Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

SAN MATEO, Calif., Sept. 3, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that Company management will be presenting at the H.C. Wainwright 28th Annual Global Investment Conference.

H.C. Wainwright 28th Annual Global Investment Conference
Date: Monday, September 14, 2026 at 4:30pm ET
Location: New York, NY
Presenter: Chief Executive Officer, Vince Angotti, and Chief Medical Officer, Shakil Aslam, MD
Format: Fireside Chat and 1x1 Meetings

Webcast Information

The webcast can be accessed here or by visiting the Talphera website on the News & Events section of the Investors page. A replay of the webcast will be available for 90 days following the event.

About Talphera, Inc.

Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad® is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).

This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/talphera-to-participate-in-the-hc-wainwright-28th-annual-global-investment-conference-302868347.html

SOURCE Talphera, Inc.